Barbiturate
Barbiturates
Barbiturates have largely been replaced by
Uses
Medicine
Barbiturates, such as
Barbiturates in high doses are used for medical aid in dying, and in combination with a muscle relaxant for euthanasia and for capital punishment by lethal injection.[7][8] Barbiturates are frequently employed as euthanizing agents in small-animal veterinary medicine.
Interrogation
The memory-impairing effects and cognitive impairments induced by sodium thiopental are thought to reduce a subject's ability to invent and remember lies. This practice is no longer considered legally admissible in court, owing to findings that subjects undergoing such interrogations may form false memories, putting the reliability of all information obtained through such methods into question. Nonetheless, it is still employed in certain circumstances by defense and law enforcement agencies as a "humane" alternative to torture interrogation when the subject is believed to have information critical to the security of the state or agency employing the tactic.[11]
Chemistry
In 1988, the synthesis and binding studies of an artificial receptor binding barbiturates by six complementary hydrogen bonds was published.[12] Since this first article, different kind of receptors were designed, as well as different barbiturates and cyanurates, not for their efficiencies as drugs but for applications in supramolecular chemistry, in the conception of materials and molecular devices.
The preferred IUPAC name of the base compound, barbituric acid, is 1,3-diazinane-2,4,6-trione. Different barbiturates have different substituents in the basic structure, mainly in position 5 on the ring.[13] In modern chemistry the barbiturates are often presented by its Hirshfeld surface representations showing its intermolecular interactions [1] calculated with CrystalExplorer Program. Sodium barbital and
Classification
Barbiturates are classified based on the duration of action. Examples of each class include:[16]
- Ultra short acting (30 minutes): methohexitone
- Short acting (2 hours): secobarbitone
- Intermediate acting (3–6 hours): amobarbitone, butabarbitone
- Long acting (6 hours): phenobarbitone
Indications
Indications for the use of barbiturates include:[17]
- Seizure
- Neonatal withdrawal syndrome
- Insomnia
- Anxiety
- Inducing anesthesia
Side effects
There are special risks to consider for older adults, and women who are pregnant. When a person ages, the body becomes less able to rid itself of barbiturates. As a result, people over the age of sixty-five are at higher risk of experiencing the harmful effects of barbiturates, including drug dependence and accidental overdose.[19] When barbiturates are taken during pregnancy, the drug passes through the placenta to the fetus. After the baby is born, it may experience withdrawal symptoms and have trouble breathing. In addition, nursing mothers who take barbiturates may transmit the drug to their babies through breast milk.[20] A rare adverse reaction to barbiturates is Stevens–Johnson syndrome, which primarily affects the mucous membranes.
This article is in prose. is available. (July 2022) |
Common side effects
- Nausea
- Hypotension
- Headache
- Drowsiness
- Skin rash
Serious side effects
- Confusion
- Coma
- Hallucination
- Fainting
- Slow breathing[21]
Rare side effects
- Agranulocytosis
- Stevens–Johnson syndrome
- Liver injury
- Megaloblastic anemia[21]
Tolerance and dependence
With regular use,
The pharmacological treatment of barbiturate withdrawal is an extended process often consisting of converting the patient to a long-acting benzodiazepine (i.e. Valium), followed by slowly tapering off the benzodiazepine. Mental cravings for barbiturates can last for months or years in some cases and counselling/support groups are highly encouraged by addiction specialists. Patients should never try to tackle the task of discontinuing barbiturates without consulting a doctor, owing to the high lethality and relatively sudden onset of the withdrawal. Attempting to quit "cold turkey" may result in neurological damage due to excitotoxicity, severe physical injuries received during convulsions, and even death resulting from arrhythmias during grande Mal seizures, paralleling death caused by delirium tremens.[citation needed]
Overdose
Some symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgement, drowsiness, shallow breathing, staggering, and, in severe cases, coma or death. The lethal dosage of barbiturates varies greatly with tolerance and from one individual to another. The
Barbiturates in overdose with other CNS (central nervous system) depressants (e.g. alcohol, opiates, benzodiazepines) are even more dangerous owing to additive CNS and respiratory depressant effects. In the case of benzodiazepines, not only do they have additive effects, barbiturates also increase the binding affinity of the benzodiazepine binding site, leading to exaggerated benzodiazepine effects. (ex. If a benzodiazepine increases the frequency of channel opening by 300%, and a barbiturate increases the duration of their opening by 300%, then the combined effects of the drugs increases the channels' overall function by 900%, not 600%).
The longest-acting barbiturates have half-lives of a day or more, and subsequently result in bioaccumulation of the drug in the system. The therapeutic and recreational effects of long-acting barbiturates wear off significantly faster than the drug can be eliminated, allowing the drug to reach toxic concentrations in the blood following repeated administration (even when taken at the therapeutic or prescribed dose) despite the user feeling little or no effects from the plasma-bound concentrations of the drug. Users who consume alcohol or other sedatives after the drug's effects have worn off, but before it has cleared the system, may experience a greatly exaggerated effect from the other sedatives which can be incapacitating or even fatal.
Barbiturates induce a number of hepatic CYP enzymes (most notably CYP2C9, CYP2C19, and CYP3A4),[22] leading to exaggerated effects from many prodrugs and decreased effects from drugs which are metabolized by these enzymes to inactive metabolites. This can result in fatal overdoses from drugs such as codeine, tramadol, and carisoprodol, which become considerably more potent after being metabolized by CYP enzymes. Although all known members of the class possess relevant enzyme induction capabilities, the degree of induction overall as well as the impact on each specific enzyme span a broad range, with phenobarbital and secobarbital being the most potent enzyme inducers and butalbital and talbutal being among the weakest enzyme inducers in the class.
People who are known to have killed themselves by barbiturate overdose include Stefan Zweig, Charles Boyer, Ruan Lingyu, Dalida, Jeannine Deckers, Felix Hausdorff, Abbie Hoffman, Phyllis Hyman, C. P. Ramanujam, George Sanders, Jean Seberg, Lupe Vélez and the members of Heaven's Gate cult. Others who have died as a result of barbiturate overdose include Pier Angeli, Brian Epstein, Judy Garland, Jimi Hendrix, Marilyn Monroe, Inger Stevens, Dinah Washington, Ellen Wilkinson, and Alan Wilson; in some cases these have been speculated to be suicides as well. Those who died of a combination of barbiturates and other drugs include Rainer Werner Fassbinder, Dorothy Kilgallen, Malcolm Lowry, Edie Sedgwick and Kenneth Williams. Dorothy Dandridge died of either an overdose or an unrelated embolism. Ingeborg Bachmann may have died of the consequences of barbiturate withdrawal (she was hospitalized with burns, the doctors treating her not being aware of her barbiturate addiction).
Contraindications
The use of Barbiturates is contraindicated in the following conditions:
- variegate porphyria (because of induction of enzymes needed for porphyria synthesis by barbiturates)
- Status asthmaticus (because of respiratory depression caused by the barbiturates)[23]
Mechanism of action
Barbiturates act as positive
Further, barbiturates are relatively non-selective compounds that bind to an entire superfamily of ligand-gated ion channels, of which the GABAA receptor channel is only one of several representatives. This
Interactions
Drug interactions with barbiturates are:[21]
- alcohol
- opioids
- benzodiazepines
- anticoagulants
- antihistamines
- atazanavir
- birth-control pills
- boceprevir
Caution
Caution is needed in people using:[21]
- Medications such as opioids or benzodiazepines
- Alcohol
Caution is also required in patients with:
- Asthma
- Kidney- or liver-problems
- Heart-disease
- Substance use disorder
- Depression
- History of suicidal thoughts
History
It was not until the 1950s that the behavioral disturbances and physical dependence potential of barbiturates became recognized.[34]
Barbituric acid itself does not have any direct effect on the
Barbiturates can in most cases be used either as the free acid or as salts of sodium, calcium, potassium, magnesium, lithium, etc. Codeine- and dionine-based salts of barbituric acid have been developed.
Society and culture
Legal status
During World War II, military personnel in the Pacific region were given "goofballs" to improve their tolerance of the heat and humidity of daily working conditions. Goofballs reduced the demand on the respiratory system, as well as maintaining blood pressure. Many soldiers returned with addictions that required several months of rehabilitation before discharge. This led to growing dependency problems, often exacerbated by indifferent physicians prescribing high doses to unknowing patients through the 1950s and 1960s. [citation needed]
In the late 1950s and 1960s, an increasing number of published reports of barbiturate
In the Netherlands, the Opium Law classifies all barbiturates as List II drugs, with the exception of secobarbital, which is on List I.
There is a small group of List II drugs for which physicians have to write the prescriptions according to the same, tougher guidelines as those for List I drugs (writing the prescription in full in letters, listing the patients name, and have to contain the name and initials, address, city and telephone number of the licensed prescriber issuing the prescriptions, as well as the name and initials, address and city of the person the prescription is issued to). Among that group of drugs are the barbiturates amobarbital, butalbital, cyclobarbital, and pentobarbital.
In the United States, the
In 1971, the
Recreational use
Recreational users report that a barbiturate high gives them feelings of relaxed contentment and
Often polysubstance use occurs and barbiturates are consumed with or substituted by other available substances, most commonly alcohol.People who use substances tend to prefer short-acting and intermediate-acting barbiturates.[43] The most commonly used are amobarbital (Amytal), pentobarbital (Nembutal), and secobarbital (Seconal). A combination of amobarbital and secobarbital (called Tuinal) is also highly used. Short-acting and intermediate-acting barbiturates are usually prescribed as sedatives and sleeping pills. These pills begin acting fifteen to forty minutes after they are swallowed, and their effects last from five to six hours.
Slang terms for barbiturates include barbs, barbies, bluebirds, dolls, wallbangers, yellows, downers, goofballs, sleepers, 'reds & blues', and tooties.[44]
Examples
Short name | R1 | R2 | IUPAC name | Duration of action |
---|---|---|---|---|
allobarbital | CH2CHCH2 |
CH2CHCH2 |
5,5-diallylbarbiturate | Short-acting |
amobarbital[45] | CH2CH3 | (CH2)2CH(CH3)2 |
5-ethyl-5-isopentyl-barbiturate | Intermediate-acting |
aprobarbital | CH2CHCH2 |
CH(CH3)2 |
5-allyl-5-isopropyl-barbiturate | Intermediate-acting |
alphenal | CH2CHCH2 |
C6H5 |
5-allyl-5-phenyl-barbiturate | Intermediate-acting |
barbital | CH2CH3 | CH2CH3 | 5,5-diethylbarbiturate | Long-acting |
brallobarbital | CH2CHCH2 |
CH2CBrCH2 |
5-allyl-5-(2-bromo-allyl)-barbiturate | Short-acting |
pentobarbital[45] | CH2CH3 | CH CH3(CH2)2CH3 | 5-ethyl-5-(1-methylbutyl)-barbiturate | Short-acting |
phenobarbital[45] | CH2CH3 | C6H5 |
5-ethyl-5-phenylbarbiturate | Long-acting |
primidone | CH2CH3 | C6H5 | 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione
(it lacks oxygen at #2 position of generic barbiturate structure) |
Long-acting |
secobarbital[45] | CH2CHCH2 |
CHCH3(CH2)2CH3 |
5-[(2R)-pentan-2-yl]-5-prop-2-enyl-barbiturate; 5-allyl-5-[(2R)-pentan-2-yl]-barbiturate | Short-acting |
thiopental
|
CH2CH3 | CHCH3(CH2)2CH3 | 5-ethyl-5-(1-methylbutyl)-2-thiobarbiturate
(the oxygen at #2 position is replaced by a sulfur) |
Ultrashort-acting |
See also
- Benzodiazepine
- Psycholeptic
- Dille–Koppanyi reagent, Zwikker reagent, and others spot tests for barbiturates
Explanatory notes
- ^ The most often cited standard pronunciation is /bɑːrˈbɪtjʊrɪt/ bar-BIT-yuu-rit; however, at least in the United States, the more commonly used colloquial pronunciation is /bɑːrˈbɪtjuɪt/ bar-BIT-ew-it.[1]
References
- ^ Vaux, Bert and Scott Golder. 2003. The Harvard Dialect Survey Archived 30 April 2016 at the Wayback Machine. Cambridge, MA: Harvard University Linguistics Department.
- PMID 5127086.
- ^ "DIGNITAS". Archived from the original on 9 October 2018. Retrieved 14 June 2011.
- PMID 239307.
- S2CID 38775294.
- PMID 18265473.
- ^ "Administration and Compounding Of Euthanasic Agents". Archived from the original on 7 June 2008. Retrieved 15 July 2008.
- ^ Daniel Engber (3 May 2006). "Why do lethal injections have three drugs?". Slate Magazine. Archived from the original on 6 November 2018. Retrieved 15 July 2008.
- ^ Brown, David (20 November 2006). "Some Believe 'Truth Serums' Will Come Back". The Washington Post. Retrieved 26 July 2023.
- ^ "Neuroscience for Kids – Barbiturates". Archived from the original on 16 June 2008. Retrieved 2 June 2008.
- PMID 9739631.
- .
- ^ "Barbiturates drug profile | www.emcdda.europa.eu". www.emcdda.europa.eu. Retrieved 22 December 2021.
- ^ "Wolf D. Kuhlmann, "Buffer Solutions"" (PDF). 10 September 2006. Archived from the original (PDF) on 9 November 2016. Retrieved 28 July 2014.
- ^ Steven E. Ruzin (1999). Plant Microtechnique and Microscopy. Oxford University Press. Archived from the original on 3 June 2019. Retrieved 28 July 2014.
- ^ "JaypeeDigital | Drugs Acting on Central Nervous System Sedative-Hypnotics, Alcohols, Antiepileptics and Antiparkinsonian Drugs". www.jaypeedigital.com. Retrieved 22 December 2021.
- PMID 30969553, retrieved 21 December 2021
- S2CID 5903121.
- ^ WebMD. "Toxicity, Barbiturate". eMedicine. Archived from the original on 20 July 2008. Retrieved 15 July 2008.
- S2CID 20617888.
- ^ a b c d "Barbiturates: Side Effects, Dosages, Treatment, Interactions, Warnings". RxList. Retrieved 22 December 2021.
- ^ "Livertox". Archived from the original on 2 July 2019. Retrieved 21 June 2019.
- PMID 30969553, retrieved 21 December 2021
- S2CID 4675696.
- PMID 23677991.
- ISBN 978-0-07-142280-2.
- ^ Neil Harrison; Wallace B Mendelson; Harriet de Wit (2000). "Barbiturates". Neuropsychopharmacology. Retrieved 15 July 2008.
...Barbiturates therefore promote entry of GABA-activated channels into a long-lived open state, whereas [benzodiazepines] increase only the frequency of channel opening into the initial open state. These mechanistic studies reveal interesting details of the changes in channel gating caused by barbiturates but as yet have yielded no insights into the molecular sites of action. An additional interesting effect of barbiturates is direct gating of the channels, i.e., the barbiturates may open the channel even in the absence of GABA. This usually occurs at significantly higher concentrations than those that potentiate the actions of GABA; these concentrations also are generally higher than those required for clinically effective anesthesia.
- ISBN 978-0-397-51820-3. Retrieved 1 July 2008.
- PMID 15644873.
- PMID 10049127.
- ^ a b "Barbiturates". Archived from the original on 7 November 2007. Retrieved 31 October 2007.
- ^ Medical Curiosities. Youngson, Robert M. London: Robinson Publishing, 1997. Page 276.
- ISBN 978-0-471-89979-2.
- ISBN 978-1-58562-276-4.
- ^ Pub. L. 91-513, 27 October 1970, Sec. 202(c) Sched. III(b)(1)
- ^ 21 U.S.C. § 812
- ^ 21 U.S.C. § §1308.12
- ^ "List of Psychotropic Substances under International Control ("Green List")" (PDF). International Narcotics Control Board. 25 January 2014. Archived from the original (PDF) on 24 September 2015. Retrieved 19 December 2013.
- PMID 11252979.
- S2CID 168126.
- ^ Emedicine Health. "Barbiturate Abuse". p. 1. Archived from the original on 2 August 2008. Retrieved 15 July 2008.
- PMID 498734.
- PMID 9255991.
- S2CID 29194849.
- ^ ISBN 9780080554259. Retrieved 21 December 2013.
- PMID 30969553, retrieved 8 July 2021
External links and further reading
- U.S. Drug Enforcement Administration Source for some public-domain text used on this page.
- López-Muñoz, F.; Ucha-Udabe, R.; Alamo, C. (2005). "The history of barbiturates a century after their clinical introduction". Neuropsychiatric Disease and Treatment. 1 (4): 329–343. PMID 18568113.
- National Institute on Drug Abuse: "NIDA for Teens: Prescription Depressant Medications".